REG - Oxford Biomedica PLC - Grant of options

Oxford BioMedicaAnnouncement

05/11/2024 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241105:nRSE0439La&default-theme=true

RNS Number : 0439L  Oxford Biomedica PLC  05 November 2024

 

Grant of options

 

Oxford, UK - 05 November 2024: Oxford Biomedica plc ("OXB" or the "Company";
LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today
announces that on 03 October 2024 nil-cost share options over ordinary shares
of 50 pence each in the Company were granted under the OXB 2024 Long Term
Incentive Plan ("LTIP").

 

2024 RSU Awards

 

               Name of individual  Title                       Number of shares subject to the DBP/LTIP/RSU award prior to 2024 award  Number of shares subject to the 2024 LTIP award  Total shares over which options now held  Percentage of current issued share capital under option

 Type of RSU
 US RSU        Mark Caswell        Site Head of UK Operations  74,172*                                                                 23,352                                           97,524                                    0.09%
 US RSU        John Maravich       Site Head of US Operations  15,020                                                                  14,862                                           29,882                                    0.03%
 UK RSU        Sabine Sydow        Chief of Staff              12,516                                                                  7,599                                            20,115                                    0.02%

*74,172 granted to Mark Caswell prior to 2024 Award comprise LTIP award with
performance conditions attached.

 

The UK RSU Awards will "vest" on 3 October 2027 and are not subject to
performance conditions. The US RSU Awards are divided into four tranches, not
subject to performance conditions and each tranche will "vest" on the
anniversary of the award on 03/10/2025, 03/10/2026, 03/10/2027 and 03/10/2028
respectively

 

The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Mark Caswell
 2.  Reason for the notification
 a)  Position/status                          Site Head of UK Operations
 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                              Plan. No consideration was paid for the grant of awards.
 c)  Price(s) and volumes(s)                  2024 LTIP US RSU Award

Price  Volume
                                              Nil    23,352
 d)  Aggregated information

     -    Aggregate volume                    Awards granted over 23,352 shares in total

     -    Price

                                              N/A

 e)  Date of the transaction                  2024-10-03
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 23,352 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     John Maravich
 2.  Reason for the notification
 a)  Position/status                          Site Head of US Operations
 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                              Plan. No consideration was paid for the grant of awards.
 c)  Price(s) and volumes(s)                  2024 LTIP US RSU Award

Price  Volume
                                              Nil    14,862
 d)  Aggregated information

     -    Aggregate volume                    Awards granted over 14,862 shares in total

     -    Price

                                              N/A

 e)  Date of the transaction                  2024-10-03
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 14,862 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Sabine Sydow
 2.  Reason for the notification
 a)  Position/status                          Chief of Staff
 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                              Plan. No consideration was paid for the grant of awards.
 c)  Price(s) and volumes(s)                  2024 LTIP UK RSU Award

Price  Volume
                                              Nil    7,599
 d)  Aggregated information

     -    Aggregate volume                    Awards granted over 7,599 shares in total

     -    Price

                                              N/A

 e)  Date of the transaction                  2024-10-03
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 7,599 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

-Ends-

 

Enquiries:

 

 Oxford Biomedica plc:

 Natalie Walter, Company Secretary   Tel: +44 (0)1865 783 000

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class capabilities
span from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBSBDBDDGDGSU